停止开发Torcetrapib 辉瑞制药暴跌（在线收听）

New York City-based Pfizer Incorporated, the world's largest pharmaceutical company, has stopped research on torcetrapib, a drug they hoped to sell to treat heart disease. The drug was supposed to raise levels of what is known as "good" cholesterol. The plan was for patients to use it in combination with drugs such as Lipitor and Zocor, which lower the body's levels of "bad" cholesterol. After drug trials with 15,000 patients showed that torcetrapib increased the danger of heart problems and death in those taking Lipitor, Pfizer decided to end the tests. The news sent Pfizer's stock price down 15.6% and raised the stock price of companies such as Schering-Plough Corporation, Abbott Laboratories Inc., and AstraZeneca Plc, all of whom make rival cholesterol treatment drugs.